Abstract:Background: Lung adenocarcinoma (LUAD) continues to be the leading cause of cancer death worldwide, driven by environmental factors like smoking and genetic predispositions. LUAD has a high mortality rate, and new biomarkers are urgently needed to improve treatment strategies and patient management. Programmed cell death (PCD) is involved in tumor progression and response to treatment. Therefore, there is a need for an extensive study of the role and functions of PCD-related genes (PCDRGs) in lung adenocarcinoma so as to understand the pathophysiologic features of lung adenocarcinoma. Methods: Based on TCGA and GEO databases, this research is aimed at screening differentially expressed PCD-related genes in lung adenocarcinoma. We conducted GO, and KEGG analysis to establish the link between these genes and biological processes. By applying various machine learning algorithms such as CoxBoost analysis, we developed PCD-related indices (PCDI) that were used to verify their ability to predict prognosis with the use of other datasets. This was done in addition to exploring the biological functions of PCD genes associated with lung adenocarcinoma by assessing the relationship between immune cell components of tumor microenvironment and PCD genes together with examining how they affect drug sensitivity. Results: The research presented in this article offers significant insights into LUAD. The authors identified 113 PCDRGs that were differentially expressed in LUAD. These genes are implicated in various biological functions, including High risk ing apoptosis, ferroptosis, and pathways specific to non-small cell lung cancer. Notably, the PCDI proved effective in distinguishing between High risk and Low risk LUAD patients, demonstrating a higher accuracy in prognosis prediction compared to traditional clinical indicators such as age and gender. This high prediction accuracy was validated in both test and validation cohorts. Additionally, these genes showed significant correlations with immune cell infiltration and drug sensitivity in LUAD patients. Conclusion: We analysed the expression and function of PCDRGs in LUAD and revealed their correlation with patient survival, the immune microenvironment and drug sensitivity. The constructed PCDI model provides a scientific basis for the personalised treatment of lung adenocarcinoma, and future optimisation of treatment strategies based on these genes may improve patient clinical outcomes.

Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI‐driven stemness‐related gene signature

Identification of Stem Cell-related Gene Markers by Comprehensive Transcriptome Analysis to Predict the Prognosis and Immunotherapy of Lung Adenocarcinoma

Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma

Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing

An Artificial Intelligence Network-Guided Signature for Predicting Outcome and Immunotherapy Response in Lung Adenocarcinoma Patients Based on 26 Machine Learning Algorithms.

Unveiling the impact of cell death-related genes and immune dynamics on drug resistance in lung adenocarcinoma: a risk score model and functional insights

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Advancing predictive markers in lung adenocarcinoma: A machine learning‐based immunotherapy prognostic prediction signature

Integrated Single-Cell and Transcriptome Sequencing Analyses Determines a Chromatin Regulator-Based Signature for Evaluating Prognosis in Lung Adenocarcinoma.

Prognostic signature of lung adenocarcinoma based on stem cell-related genes

Gene Signature Based on B Cell Predicts Clinical Outcome of Radiotherapy and Immunotherapy for Patients with Lung Adenocarcinoma

Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma

Computational identification and experimental verification of a novel signature based on SARS-CoV-2–related genes for predicting prognosis, immune microenvironment and therapeutic strategies in lung adenocarcinoma patients

Leveraging an Immune Cell Signature to Improve the Survival and Immunotherapy Response of Lung Adenocarcinoma.

A novel iTreg‐related signature for prognostic prediction in lung adenocarcinoma

Prognostic Risk Signature and Comprehensive Analyses of Endoplasmic Reticulum Stress-Related Genes in Lung Adenocarcinoma

Identification of Immune-Related Gene Signature Predicting Survival in the Tumor Microenvironment of Lung Adenocarcinoma.

A scoring model for the expression of genes related to programmed cell death predicts immunotherapy response and prognosis in lung adenocarcinoma

Development of Cancer-Associated Fibroblast-Related Gene Signature for Predicting the Survival and Immunotherapy Response in Lung Adenocarcinoma.

Identification of Cancer Stem Cell-Related Biomarkers in Lung Adenocarcinoma by Stemness Index and Weighted Correlation Network Analysis.